Navigation Links
New pill to treat MS
Date:4/29/2009

A new drug for multiple sclerosis can dramatically reduce the chances of a relapse or a deterioration of the condition, according to a new study from researchers at Queen Mary, University of London.

The results of a major trial presented at the Annual Meeting of the American Academy of Neurology in Seattle show that taking a course of cladribine tablets just a few times a year can reduce the chances of a relapse by well over 50 per cent. And patients who took part in the study suffered very few side effects.

If it becomes available to patients, cladribine will be the first licensed treatment for MS which does not involve regular injections.

Multiple sclerosis is a disabling neurological condition which usually starts in young adulthood. It is the result of the body's own immune system damaging the central nervous system. This interferes with transmission of messages between the brain and other parts of the body and leads to problems with vision, muscle control, balance and memory.

For the 85,000 people in the UK who suffer from MS, the treatments which are currently available have to be given by frequent injections or intravenous infusions, and the benefits have to be weighed up against a number of side effects.

The new study involved over 1,300 MS patients who were followed up for nearly two years. Patients were given either two or four treatment courses of cladribine tablets per year, or a placebo. Each course consists of a single tablet per day for four or five days, adding up to just eight to 20 days of treatment each year. During the trial patients were monitored using MRI scans.

Compared to patients who were taking a placebo, those taking cladribine tablets were over 55 per cent less likely to suffer a relapse and 30 per cent less likely to suffer worsening in their disability due to MS.

The study's lead researcher is Professor Gavin Giovannoni of Barts and The London School of Medicine and Dentistry, part of Queen Mary, University of London. He said: "These results are really exciting. MS can be a very debilitating illness and at the moment treatment options remain limited. Having an effective oral therapy will have a major impact for people with MS."

"Our study shows that cladribine tablets prevent relapses and slow down the progression of the disease making patients feel better. Importantly, it does so without the need for constant injections that are associated with unpleasant side effects"

"We will continue to follow the patients in the trial to see how they fare in the long-term."

Cladribine tablets work by suppressing the immune system, reducing the risk of further damage to a patient's nervous system.


'/>"/>

Contact: Kerry Noble
k.noble@qmul.ac.uk
07-932-640-759
Queen Mary, University of London
Source:Eurekalert

Related medicine news :

1. New therapy based on magnetic stimulation shows promise for non-drug treatment for migraine
2. New Treatment Combo Better Against Hepatitis C
3. New Treatment Discovered for Restless Legs Syndrome Improves Sleep
4. Reverend Clyde M. Allison: Founder of Trick-or-Treat for UNICEF
5. Free Treatment for Breast Cancer Available in Pennsylvania
6. Zebrafish offer clues to treatments for motor neurone disease
7. New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
8. Tysabri May Treat Myelin Sheath Damage From MS
9. Varicose Veins Pose Scary Health Risk; Sufferers Find Solace With Insurance-Covered Treatment at Renaissance Laser and Vein Institute
10. Topical cream studied as way to treat skin cancer without the knife
11. Study finds higher drug co-pays discourage patients from starting treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... ... and consumers are seeing lots of red these days. According to recent estimates, ... that result from medical coding errors(1). Some studies point to Electronic Health Records ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing ... Cotey, with or without a referral. Dr. Cotey is a trusted dentist who has ... tooth replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged to ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut ... sound in the timeline and write in the lyrics to any song. ProLyric flies in ... Each line of the text can be added modularly for optimal control. ProLyric makes editing ...
(Date:6/25/2017)... ... ... An increase in wetter weather in the Northern California area naturally means ... humdinger of an allergy season. A relief from drought conditions is most welcome, but ... weed pollen. , “Our patients have been reporting the typical allergy season symptoms, ...
(Date:6/25/2017)... ... ... a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many people ... easy with laser hair removal. , The process of summer waxing and constantly shaving ... you want to do is get out, dive in and cool off. There is a ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away with ... platform is described by Forbes as "entering the life ... Medical Association as teaching "empathy to medical professionals in ... startup was recently named a finalist for the Department ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
Breaking Medicine Technology: